Tag: China

Wuxi and the Development of Antibody-Drug Conjugates: A Balanced Perspective

Becotatug Vedotin: First EGFR-Targeted ADC Approved in China for Recurrent or Metastatic Nasopharyngeal Carcinoma

China’s out-licensing deals have significantly increased over the last five years, showcasing the country as a source of innovative drugs. The licensing agreements provide...

Disitamab Vedotin Gains Approval in China for its Third Indication

Japanese drugmaker Daiichi Sankyo this week confirmed that the company will invest approximately US $ 152 million (RMB 1.1 billion) in the construction of a new manufacturing facility for antibody-drug conjugate (ADC-) production in Zhangjiang, Shanghai.

Over the past five years China has emerged as a major force in the research and development of innovative therapies for the treatment of...

Following intensified investments, new partnerships, out-licensing ADC assets, and major scientific advances from companies including Bristol Myers Squibb (a US $8.4 billion deal with SystImmune), AstraZeneca (the company signed a US $ 600 million dollar deal to obtain global from LaNova Medicines for pre-clinical ADC candidates), Roche, Lonza, MilliporeSigma, BioNTech (acquired 2 different ADC assets from DualityBio for an upfront payment of US $170 million. The company also obtained a novel ADC HER3 assets from MediLink Therapeutics), Myricx Bio (licensed rights to an antibody discovered by WuXi Biologics),  while GlaxoSmithKline (acquired ex-China rights for B7-H4 ADC from Hansoh Pharma in a $1.57 billion deal, plus royalties on sales), and others, China is expected to drive the next research boom in novel, innovative medicines, like antibody-drug conjugates (ADC).

Japanese drugmaker Eisai & Co and Chinese drug developer Bliss Biopharmaceutical (Hangzhou) Co., have entered into a joint development agreement to further develop BB-1701, an antibody-drug conjugate (ADC). As part of the agreement Eisai & Co obtained option rights for a strategic collaboration.

Chinese WuXi XDC, a joint venture between WuXi Biologics and WuXi STA, a Contract Research, Development and Manufacturing Organization focusing on end-to-end bioconjugates services, and...

China's National Medical Products Administration (NMPA) has approved sacituzumab govitecan (Trodelvy®; Gilead Sciences) for the treatment of adult patients with unresectable locally advanced or metastatic...